14,049 Call Contracts Traded on Sun Pharmaceutical Industries Ltd as Stock Nears Rs 1,820 Strike

Options Event and Cash Market Price Action

The call option series expiring on 30 Mar 2026 saw a turnover of approximately Rs 293.06 lakhs, reflecting significant interest concentrated in a near-term expiry. The strike price of Rs 1,820 sits just 14 points above the underlying stock price of Rs 1,806, placing these calls effectively at-the-money (ATM). This proximity suggests that traders are positioning for immediate directional movement rather than a distant target, with the option’s gamma sensitivity maximised around this strike.

Notably, the stock has outperformed its sector by 0.99% today and is trading just 2.44% below its 52-week high of Rs 1,851.2. The recent two-day gain of 3.07% aligns with the surge in call contracts, indicating that the derivatives market is reflecting the underlying bullish momentum rather than anticipating it. Is this alignment a sign of sustained momentum or a short-lived burst ahead of expiry?

Strike Price and Moneyness Analysis

The Rs 1,820 strike price is marginally out-of-the-money relative to the closing price of Rs 1,806, but close enough to be considered ATM for practical purposes. This strike selection reveals a bet on near-term upside, with traders likely anticipating a push above this level before expiry in three trading days. ATM calls are the most sensitive to price changes, so the volume here suggests a conviction in immediate directional moves rather than speculative long-term positioning.

Given the stock’s proximity to its 52-week high, the choice of this strike could also reflect a tactical approach to capitalise on short-term momentum while limiting premium outlay. What does this strike price tell us about traders’ confidence in the stock’s near-term trajectory?

Open Interest and Contracts Analysis

Open interest (OI) at this strike stands at 3,589 contracts, while the day’s traded volume was 14,049 contracts. This results in a contracts-to-OI ratio of nearly 3.9:1, a figure that strongly indicates fresh positioning rather than mere rotation of existing holdings. Such a high ratio suggests that new money is entering the call options market, reinforcing the directional bet on the stock’s upside.

The elevated turnover and fresh positioning ahead of expiry underscore a sense of urgency among traders to establish or increase bullish exposure. This contrasts with scenarios where traded volume is low relative to OI, which would imply profit-taking or position adjustments. Does this fresh influx of call buying signal a broader shift in market sentiment for Sun Pharmaceutical Industries Ltd?

Cash Market Context: Momentum and Moving Averages

Sun Pharmaceutical Industries Ltd is trading comfortably above its key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — a technical backdrop that supports the bullish options activity. The stock’s recent gains have been steady, with a 0.52% rise today and a 3.07% increase over two days, reflecting positive momentum that the call options market appears to be mirroring.

However, delivery volumes tell a more nuanced story. On 25 Mar, delivery volume was 11.2 lakh shares, down 38.04% against the five-day average, indicating a decline in investor participation in the cash market. This divergence between rising call activity and falling delivery volumes suggests that the derivatives market is currently the primary arena for expressing bullish conviction, rather than the cash market. Is this a sign that the options market is leading price discovery or that cash market conviction is yet to catch up?

Delivery Volume and Liquidity Considerations

Despite the surge in call option contracts, the cash market’s delivery volume has contracted sharply, which may indicate that traders are currently more comfortable expressing directional views through derivatives rather than outright stock purchases. The stock remains liquid, with a trade size capacity of approximately Rs 9.27 crore based on 2% of the five-day average traded value, ensuring that both cash and derivatives markets can absorb sizeable trades without undue price impact.

This liquidity profile supports the observed options activity, as participants can efficiently enter and exit positions in both segments. Could this liquidity balance be a factor in the preference for call options over cash market exposure?

Key Data at a Glance

Conclusion: What the Options and Cash Data Collectively Signal

The heavy call option activity at the Rs 1,820 strike price, combined with the stock’s recent gains and position above key moving averages, paints a picture of near-term bullish positioning in Sun Pharmaceutical Industries Ltd. The contracts-to-OI ratio indicates fresh money entering the market, while the proximity of the strike to the current price highlights a focus on immediate directional moves rather than speculative distant targets.

However, the decline in delivery volumes suggests that the cash market is not fully confirming this optimism, raising the question of whether the derivatives market is leading price discovery or if the cash market will eventually follow suit. Is this divergence a signal to buy, sell, or hold Sun Pharmaceutical Industries Ltd at this juncture?

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today